RxDoctor Payments Data

Andrew Billnitzer, MD

Neurology · Houston, TXNPI 1659758811

Payments from drug & device makers

$57,048in general payments, 2019–2025

Across 576 payments — averaging $99.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$32K
  • Boston Scientific$11K
  • Biogen$3K
  • AbbVie$2K
  • Acadia Pharmaceuticals Inc$1K
  • Neurocrine Biosciences, Inc.$1K
  • plus $7K from 40 others

What the payments were for

  • Consulting fees$3,2546%
  • Speaking & faculty fees$3581%
  • Grants$41,25072%
  • Travel & lodging$5011%
  • Food & beverage$11,67420%
  • Education$110%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$57,048 in reported general payments places this provider in the 80th percentile of 1,246 neurology providers in Texas.

See all neurology providers in Texas

Medicare billing

Part B allowed, 2024
$225,588
Medicare patients
350
Services billed
16,827

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine81$692,963
NuplazidPimavanserin Tartrate85$449,717
IngrezzaValbenazine Tosylate56$422,674
SkyclarysOmaveloxolone12$387,212
RytaryCarbidopa/Levodopa318$333,516
BotoxOnabotulinumtoxina63$84,611
GocovriAmantadine Hcl22$79,960
OngentysOpicapone39$25,786
Carbidopa-LevodopaCarbidopa/Levodopa488$19,555
NuedextaDextromethorphan Hbr/Quinidine11$16,754
GemtesaVibegron14$11,097
MyrbetriqMirabegron18$9,676
Carbidopa-Levodopa ErCarbidopa/Levodopa168$8,774
Rasagiline Mesylate42$6,877
Droxidopa21$6,101

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$725$692,96381 claims
Acadia Pharmaceuticals IncNuplazid$1,123$449,71785 claims
Neurocrine Biosciences, Inc.Ingrezza, Ongentys$1,041$448,46095 claims
BiogenSkyclarys$3,416$387,21212 claims
Amneal Pharmaceuticals LLCRytary$633$333,516318 claims
AbbVieBotox$1,862$84,61163 claims
MDD US Operations, LLCGocovri$246$79,96022 claims
Avanir Pharmaceuticals, Inc.Nuedexta$53$16,75411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,246 neurology providers in Texas.

Other neurology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →